What is 5-Amino-1MQ?
5-Amino-1MQ is not a peptide but a compact small molecule, built to slip inside cells and switch off one specific enzyme: nicotinamide N-methyltransferase, NNMT. That enzyme sits at a busy metabolic junction, and in the fat tissue of obese and insulin-resistant animals and people it runs conspicuously hot.
NNMT's day job is tagging nicotinamide, a vitamin B3 form the body uses to make NAD+, with methyl groups. Run too fast, it drains two resources at once: the NAD+ supply that powers energy production, and the methyl groups cells use for regulation. 5-Amino-1MQ exists to slow that drain, and the fat-loss interest follows directly from the biology.
How does it work?
The target validation is the impressive part. A 2014 study in Nature showed that knocking down NNMT genetically in fat and liver tissue protected mice against diet-induced obesity, raised their energy expenditure, and improved insulin sensitivity, tracing the effect to NAD+ and methyl-group metabolism, the two threads NNMT tugs.
5-Amino-1MQ aims to reproduce that genetic result with a pill-style molecule: block the enzyme, preserve nicotinamide for NAD+ production, free the methyl groups, and lift the metabolic brake on fat cells. Reviews describe NNMT as a genuine regulator of energy metabolism in fat tissue, which is why inhibiting it is explored for obesity, type 2 diabetes, and metabolic syndrome broadly.
Why it matters
The GLP-1 era solved appetite; it did not solve energy expenditure. A compound that makes fat tissue burn more fuel without touching hunger would be the other half of the metabolic toolkit, and that is precisely the profile the NNMT animal work shows: fat loss without eating less. It also connects to the NAD+ story covered elsewhere in this library from the opposite direction, preserving NAD+ by slowing its drain rather than supplementing precursors.
What the research shows
The defining result is a 2018 study in Biochemical Pharmacology: in diet-induced obese mice, selective membrane-permeable NNMT inhibitors of this class reversed obesity, with treated animals losing fat mass and body weight without a reduction in food intake, pointing at energy spent rather than appetite suppressed. Later animal work has extended the picture across metabolic measures.
And that is where the evidence stops: cells and animals. No human trial of 5-Amino-1MQ has been run, no human safety dataset exists, and every capsule sold today is riding mouse data. The target is validated; the compound, in humans, is not.
What people notice in practice
5-Amino-1MQ has become a popular gray-market fat-loss compound, usually in capsules, often stacked with NAD+ precursors. What users report, labeled honestly as experience rather than trial evidence, is gradual recomposition, steadier energy, and easier fat loss alongside training, claims that sit squarely on the most self-report-prone endpoints in wellness.
The blunt version: this is one of the most widely used never-tested-in-humans compounds in the metabolic space, and the absence of human safety data is not a technicality for a molecule that reaches into NAD+ and methylation chemistry, two systems with fingers in everything.
The pros and the cons
What's promising
- A genuinely validated target: genetic NNMT knockdown protects mice from obesity.
- Fat loss without appetite change in the animal work, the profile the field lacks.
- A rational NAD+-preserving mechanism connecting to established biology.
- Active research interest in NNMT across metabolic disease.
What's uncertain
- No human trials of any kind: efficacy, dosing, and safety are all extrapolation.
- Methylation and NAD+ chemistry touch nearly everything, making unknowns wide.
- Gray-market capsule quality is untested by anyone.
- The animal results, while consistent, come from a small number of groups.
Worth considering
- Human-tested metabolic tools exist, several covered in this library; this one competes with them, not with nothing.
- Anyone experimenting anyway belongs under physician oversight with baseline labs.
- Watch for the first human trials; the target is interesting enough that they may come.
- Energy-expenditure claims deserve extra skepticism; they are the easiest to feel and hardest to measure.
Why the evidence lags the sales
NNMT inhibition is patentable territory and pharmaceutical groups are working it, but the specific research-tool molecule sold as 5-Amino-1MQ raced ahead of that pipeline into the supplement gray market, where mouse studies plus a mechanism make a marketing page. The familiar rule in its sharpest form: a validated target is a reason to run human trials, not a substitute for them.
What the key studies tested
Our framing rule for evidence: a study tests one compound, one model, one endpoint. Where the evidence sits:
Preclinical & practice
Everything: the Nature knockdown work, the 2018 obesity reversal, and all human use.
Early trials
None in humans.
Late-stage trials
None.
Approved uses
None, anywhere.
Every study behind this article is filterable in our research library on the Science page.
Questions people ask
How is this different from taking NAD+ precursors?
Opposite ends of the same pipe. Precursors like NMN add raw material for NAD+ production; NNMT inhibition slows an enzyme that drains nicotinamide away from it. The precursor approach has human trials showing it raises NAD+; the inhibitor approach has mouse studies and a validated genetic target. Same biology, very different evidence tiers.
Does 5-Amino-1MQ burn fat without dieting?
In mice, that is genuinely what the studies show: fat mass and body weight fell without reduced food intake, implying increased energy expenditure. In humans, nobody has run any trial, so the honest answer is that the most attractive claim in the marketing has never been tested in a single person.
Is it safe?
Unknown in the strictest sense: no human safety study exists at any dose. The mechanism reaches into NAD+ and methylation chemistry, which regulate processes across the body, so the theoretical surface for surprises is wide. Anyone experimenting despite that belongs under physician oversight with baseline and follow-up labs.
Will there be human trials?
The target deserves them: NNMT inhibition is under active pharmaceutical research for metabolic disease, and the genetic validation is strong. Whether this particular research-tool molecule is the one carried forward, or a refined successor, is exactly what the coming years of that pipeline will decide.
What to take away
If you remember five things from this article, make them these:
- 5-Amino-1MQ blocks NNMT, an enzyme that runs hot in obese fat tissue and drains NAD+ and methyl groups.
- The target is validated by genetics: NNMT knockdown protects mice from obesity outright.
- The compound reversed obesity in mice without reducing food intake, the profile the field wants most.
- Not one human trial exists; efficacy, dosing, and safety are all mouse-data extrapolation.
- Human-tested metabolic tools exist today, and this molecule's job is to earn its trials, not replace them.
The evidence
Selected references, each verified against primary sources (PubMed). Explore the full, filterable research library on our Science page.
This article is for educational purposes only and is not medical advice, a diagnosis, or a treatment recommendation. 5-Amino-1MQ is discussed in the context of the published research; inclusion of a study does not imply a guaranteed outcome. Many of these compounds are investigational and not approved for the uses described in all jurisdictions. Any treatment decision should be made with a qualified physician. Individual results vary.